Equity research analysts tracking ADC Therapeutics (ADCT) provide twelve-month consensus price targets and forecasts that reflect its ongoing clinical trial developments and commercial sales trajectory for its flagship cancer treatment Zynlonta. While specific target figures update dynamically following quarterly earnings releases and clinical data readouts, analysts generally weigh the high potential upside of its proprietary antibody-drug conjugate pipeline against the short-term financial risks of cash burn and clinical regulatory hurdles typical of biotechnology equities.